IQVIA Holdings Inc., often recognized by its stock symbol IQV, operates in the life sciences industry, providing advanced analytics, technology solutions, and clinical research services. With a presence in over 100 countries and approximately 87,000 employees, IQVIA creates intelligent connections across all aspects of healthcare. The company's analytics, transformative technology, big data resources, extensive domain expertise, and network of partners enable life sciences companies to make critical decisions and perform better. IQVIA's main business...
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | TMO | Thermo Fisher Scientific Inc. | 216.83 Bn | 33.00 | 4.96 | 35.68 Bn |
| 2 | DHR | Danaher Corp /De/ | 162.47 Bn | 46.38 | 6.69 | 16.86 Bn |
| 3 | IDXX | Idexx Laboratories Inc /De | 56.88 Bn | 55.36 | 13.65 | 1.09 Bn |
| 4 | A | Agilent Technologies, Inc. | 39.82 Bn | 32.64 | 5.87 | 3.41 Bn |
| 5 | IQV | Iqvia Holdings Inc. | 38.85 Bn | 30.28 | 2.44 | 15.19 Bn |
| 6 | NTRA | Natera, Inc. | 31.32 Bn | -101.29 | 14.80 | 0.18 Bn |
| 7 | MTD | Mettler Toledo International Inc/ | 28.99 Bn | 34.68 | 7.35 | 2.21 Bn |
| 8 | WAT | Waters Corp /De/ | 22.92 Bn | 35.32 | 7.38 | 1.49 Bn |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| EV to Assets | 1.83 | 2.69 | |
| EV to Cash from Ops. | 18.73 | 18.14 | |
| EV to Debt | 3.46 | 52.51 | |
| EV to EBIT | 22.88 | 19.22 | |
| EV to EBITDA | 15.86 | 4.35 | |
| EV to Free Cash Flow [EV/FCF] | 22.97 | 2.84 | |
| EV to Market Cap | 1.35 | 1.52 | |
| EV to Revenue | 3.30 | 4.79 | |
| Price to Book Value [P/B] | 6.31 | 1.34 | |
| Price to Earnings [P/E] | 30.28 | 22.02 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio | 0.00 | -1.96 | |
| Dividend Payout Ratio % | 0.00 | 2.83 | |
| Dividend per Basic Share | 0.00 | 0.19 | |
| FCF Dividend Payout Ratio % | 0.00 | 1.92 | |
| Interest Coverage | 3.25 | -126.58 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Capex Growth (1y) % | 12.50 | -31.50 | |
| Cash and Equivalents Growth (1y) % | 15.39 | 21.37 | |
| Dividend Growth (1y) % | 0.00 | 0.24 | |
| EBIAT Growth (1y) % | -9.35 | -55.24 | |
| EBITDA Growth (1y) % | 3.34 | -447.96 | |
| EBIT Growth (1y) % | 5.66 | -40.50 | |
| EBT Growth (1y) % | 6.43 | -70.94 | |
| EPS Growth (1y) % | -4.80 | -70.02 | |
| FCF Growth (1y) % | 15.11 | 56.33 | |
| Gross Profit Growth (1y) % | -0.28 | 185.11 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Asset Utilization Ratio | 0.55 | 0.56 | |
| Cash Payout Ratio | 0.00 | 0.01 | |
| Cash Ratio | 0.21 | 1.21 | |
| Current Ratio | 0.70 | 2.64 | |
| Debt to Equity Ratio | 2.47 | -0.80 | |
| Interest Cover Ratio | 3.25 | -126.58 | |
| Times Interest Earned | 3.25 | -126.58 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| EBITDA Margin % | 21.50 | -129.91 | |
| EBIT Margin % | 14.43 | -156.71 | |
| EBT Margin % | 9.98 | -162.23 | |
| Gross Margin % | 33.80 | 47.70 | |
| Net Profit Margin % | 8.10 | -189.30 |